Integration of adeno-associated virus (AAV) and recombinant AAV vectors

被引:313
作者
McCarty, DM [1 ]
Young, SM
Samulski, RJ
机构
[1] Univ N Carolina, Sch Pharm, Chapel Hill, NC 27599 USA
[2] Univ N Carolina, Gene Therapy Ctr, Chapel Hill, NC 27599 USA
[3] Salk Inst, San Diego, CA 92186 USA
[4] Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA
关键词
AAV; integration; vector; site-specific; gene therapy;
D O I
10.1146/annurev.genet.37.110801.143717
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
The driving interest in adeno-associated virus (AAV) has been its potential as a gene delivery vector. The early observation that AAV can establish a latent infection by integrating into the host chromosome has been central to this interest. However, chromosomal integration is a two-edged sword, imparting on one hand the ability to maintain the therapeutic gene in progeny cells, and on the other hand, the risk of mutations that are deleterious to the host. A clearer understanding of the mechanism and efficiency of AAV integration, in terms of contributing viral and host-cell factors and circumstances, will provide a context in which to evaluate these potential benefits and risks. Research to date suggests that AAV integration in any context is inefficient, and that the persistence of AAV gene delivery vectors in tissues is largely attributable to episomal genomes.
引用
收藏
页码:819 / 845
页数:27
相关论文
共 110 条